期刊文献+

干扰素相关结肠病变的特点及防治

Interferon-induced colonic lesions: clinical features, prevention, and treatment
原文传递
导出
摘要 干扰素多用于治疗病毒性肝炎,其显著的免疫调节作用可以引起溃疡性结肠炎、克罗恩病和缺血性结肠炎等结肠病变。干扰素相关溃疡性结肠炎较为多见,多发生于干扰素治疗后2周至数年,以腹痛、腹泻、黏液便为主要表现,肠镜检查可见结肠黏膜弥漫性水肿伴溃疡、充血,应用美沙拉秦、柳氮磺嘧啶或糖皮质激素治疗有效,多数患者症状改善后可继续干扰素治疗。干扰素相关克罗恩病较为少见,预后不佳。干扰素相关缺血性结肠炎病变多局限在降结肠,表现为纵向溃疡、黏膜水肿及糜烂出血等,停药后对症治疗,症状多于2周内缓解,并可继续干扰素治疗。 The interferon is a commonly used drug which is used to treat viral hepatitis. Due to its significant role in the regulation of immune system, it can conduce to inflammatory bowel diseases, such as ulcerative colitis, Crohn~ disease, and ischemic colitis. Interferon-related ulcerative colitis is more common, generally occurs from two weeks to several years after interferon therapy, the patients complain of abdominal pain and diarrhea, mucus stool is the main manifestation. A total eolonoscopy shows diffuse mucosal edema, ulcer, and hyperemia. The patients are treated with mesalazine, sulfasalazine or glucocortieoids. Some patients may continue interferon therapy after the symptoms improved. Interferon-related Crohn's disease is rare and the prognosis is poor. Interferon-related isehemic colitis lesions generally are confined to the descending colon, long-term ulcers, mucosal edema and erosion bleeding. The symptoms are relieved within 2 weeks after interferon discontinuation and symptomatic therapy. Then interferon therapy can be continued.
出处 《药物不良反应杂志》 CSCD 2015年第6期440-443,共4页 Adverse Drug Reactions Journal
基金 首都中医药研究专项(13ZY05) 北京市卫生系统高层次卫生技术人才培养项目(学科骨干)(2013-3-022)
关键词 干扰素类 炎性肠疾病 Interferons Inflammatory bowel diseases
  • 相关文献

参考文献1

二级参考文献15

  • 1Sung H, Chang M, Saab S. Management of Hepatitis C Antiviral Therapy Adverse Effects. Curr Hepat Rep 2011, 10: 33-40.
  • 2Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Saka- moto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepa- to11996, 25:283-291.
  • 3Horigome H, Takezono Y, Fujino N, Uchida A, Murasaki G. [A case of ischemic colitis associated with interferon treat- ment]. Nihon Shokakibyo Gakkai Zasshi 1996, 93:181-184.
  • 4Wenner WJ, Piccoli DA. Colitis associated with alpha inter- feron? J Clin Gastroentero11997, 25:398-399.
  • 5Punnam SR, Pothula VR, Gourineni N, Punnam A, Ranga- nathan V. Interferon-ribavirin-associated ischemic colitis. J Clin Gastroentero12008, 42:323-325.
  • 6Tada H, Saitoh S, Nakagawa Y, Hirana H, Morimoto M, Shima T, Shimamoto K, Okanoue T, Kashima K. Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C. J Gastroentero11996, 31:582-584.
  • 7Leung Y, Urbanski SJ, Schindel L, Myers RP. Ischemic coli- tis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Can J Gastroentero12006, 20:661-663.
  • 8Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gas- troentero12007, 102:2718-2723.
  • 9Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007, 370:342-350.
  • 10Sparano JA, Dutcher JP, Kaleya R, Caliendo G, Fiorito J, Mitsudo S, Shechner R, Boley SJ, Gucalp R, Ciobanu N. Co- lonic ischemia complicating immunotherapy with interleu- kin-2 and interferon-alpha. Cancer 1991, 68:1538-1544.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部